Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agiliti, Inc. stock logo
AGTI
Agiliti
$10.10
-0.5%
$9.87
$5.07
$18.61
$1.37B1.951.38 million shs3.01 million shs
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$13.86
-11.2%
$17.68
$3.03
$30.40
$1.18B2.1182,865 shs125,154 shs
National HealthCare Co. stock logo
NHC
National HealthCare
$92.02
+1.3%
$0.00
$55.50
$101.81
$1.42B0.3672,206 shs66,820 shs
NovoCure Limited stock logo
NVCR
NovoCure
$12.74
+4.1%
$14.23
$10.87
$83.60
$1.37B0.421.33 million shs1.29 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agiliti, Inc. stock logo
AGTI
Agiliti
-0.49%0.00%+0.10%+42.66%+392.68%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-11.15%-13.64%-12.56%+13.70%+1,385,999,900.00%
National HealthCare Co. stock logo
NHC
National HealthCare
0.00%0.00%0.00%0.00%+1.51%
NovoCure Limited stock logo
NVCR
NovoCure
+4.08%+3.24%-17.75%-13.10%-80.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agiliti, Inc. stock logo
AGTI
Agiliti
1.7731 of 5 stars
2.94.00.00.01.82.50.0
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
0.1401 of 5 stars
0.03.00.00.01.70.00.6
National HealthCare Co. stock logo
NHC
National HealthCare
1.4241 of 5 stars
0.03.01.70.02.31.71.3
NovoCure Limited stock logo
NVCR
NovoCure
4.1432 of 5 stars
4.31.00.04.52.42.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agiliti, Inc. stock logo
AGTI
Agiliti
1.86
Reduce$14.1740.26% Upside
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
N/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
2.56
Moderate Buy$31.13144.31% Upside

Current Analyst Ratings

Latest NHC, NVCR, AGTI, and GYRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $28.00
4/3/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $42.00
3/27/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$21.00
3/27/2024
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$22.00 ➝ $24.00
3/26/2024
Agiliti, Inc. stock logo
AGTI
Agiliti
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
3/19/2024
NovoCure Limited stock logo
NVCR
NovoCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$15.00 ➝ $17.00
3/7/2024
Agiliti, Inc. stock logo
AGTI
Agiliti
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00
2/23/2024
NovoCure Limited stock logo
NVCR
NovoCure
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$14.00 ➝ $15.00
2/22/2024
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
2/6/2024
Agiliti, Inc. stock logo
AGTI
Agiliti
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Weight
(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agiliti, Inc. stock logo
AGTI
Agiliti
$1.17B1.17$1.74 per share5.80$6.98 per share1.45
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$113.45M10.44$0.21 per share66.05$0.18 per share77.00
National HealthCare Co. stock logo
NHC
National HealthCare
$1.14B1.24$6.25 per share14.73$59.41 per share1.55
NovoCure Limited stock logo
NVCR
NovoCure
$509.34M2.69N/AN/A$3.39 per share3.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agiliti, Inc. stock logo
AGTI
Agiliti
-$19.42M-$0.14N/A21.49N/A-1.65%6.47%2.53%5/14/2024 (Estimated)
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$92.93M-$20.69N/AN/AN/AN/AN/A-228.91%5/20/2024 (Estimated)
National HealthCare Co. stock logo
NHC
National HealthCare
$66.80M$4.3321.25N/A5.85%6.03%4.18%N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.95N/AN/AN/A-40.65%-51.63%-17.90%5/2/2024 (Confirmed)

Latest NHC, NVCR, AGTI, and GYRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$0.42N/A+$0.42N/AN/AN/A  
3/5/2024Q4 2023
Agiliti, Inc. stock logo
AGTI
Agiliti
$0.10$0.11+$0.01$0.26$291.99 million$291.99 million
2/22/2024Q4 2023
NovoCure Limited stock logo
NVCR
NovoCure
-$0.53-$0.45+$0.08-$0.45$133.80 million$133.80 million      
2/16/2024Q4 2023
National HealthCare Co. stock logo
NHC
National HealthCare
N/A$0.98+$0.98$0.13N/A$300.91 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agiliti, Inc. stock logo
AGTI
Agiliti
N/AN/AN/AN/AN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
$2.362.56%+4.00%54.50%3 Years
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A

Latest NHC, NVCR, AGTI, and GYRE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/9/2024
National HealthCare Co. stock logo
NHC
National HealthCare
quarterly$0.592.5%3/27/20243/29/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agiliti, Inc. stock logo
AGTI
Agiliti
1.13
1.72
1.34
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
2.85
2.64
National HealthCare Co. stock logo
NHC
National HealthCare
N/A
1.89
1.86
NovoCure Limited stock logo
NVCR
NovoCure
1.57
5.78
5.56

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Agiliti, Inc. stock logo
AGTI
Agiliti
99.12%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
National HealthCare Co. stock logo
NHC
National HealthCare
56.44%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Agiliti, Inc. stock logo
AGTI
Agiliti
4.16%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
2.92%
National HealthCare Co. stock logo
NHC
National HealthCare
13.75%
NovoCure Limited stock logo
NVCR
NovoCure
5.67%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Agiliti, Inc. stock logo
AGTI
Agiliti
5,800136.08 million130.42 millionOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
59385.42 million82.93 millionNo Data
National HealthCare Co. stock logo
NHC
National HealthCare
13,12315.40 million13.28 millionNot Optionable
NovoCure Limited stock logo
NVCR
NovoCure
1,453107.61 million101.51 millionOptionable

NHC, NVCR, AGTI, and GYRE Headlines

SourceHeadline
NovoCure Limited (NASDAQ:NVCR) Sees Significant Growth in Short InterestNovoCure Limited (NASDAQ:NVCR) Sees Significant Growth in Short Interest
americanbankingnews.com - May 1 at 3:22 AM
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Analysts
americanbankingnews.com - April 30 at 2:40 AM
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Moderate Buy" from AnalystsNovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Moderate Buy" from Analysts
marketbeat.com - April 30 at 2:33 AM
NovoCure Limited (NASDAQ:NVCR) Shares Purchased by C WorldWide Group Holding A SNovoCure Limited (NASDAQ:NVCR) Shares Purchased by C WorldWide Group Holding A S
marketbeat.com - April 27 at 5:21 PM
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com - April 25 at 11:07 AM
Federated Hermes Inc. Has $9.21 Million Position in NovoCure Limited (NASDAQ:NVCR)Federated Hermes Inc. Has $9.21 Million Position in NovoCure Limited (NASDAQ:NVCR)
marketbeat.com - April 25 at 5:33 AM
NovoCure (NASDAQ:NVCR) Share Price Passes Below 50 Day Moving Average of $14.57NovoCure (NASDAQ:NVCR) Share Price Passes Below 50 Day Moving Average of $14.57
americanbankingnews.com - April 25 at 4:44 AM
NovoCure (NVCR) Scheduled to Post Earnings on ThursdayNovoCure (NVCR) Scheduled to Post Earnings on Thursday
americanbankingnews.com - April 25 at 1:28 AM
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
finance.yahoo.com - April 24 at 3:27 PM
Results of Novocures METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
businesswire.com - April 24 at 10:45 AM
Buy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial ExecutionBuy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution
markets.businessinsider.com - April 11 at 10:38 AM
NovoCure (NASDAQ:NVCR) Given "Overweight" Rating at Piper SandlerNovoCure (NASDAQ:NVCR) Given "Overweight" Rating at Piper Sandler
marketbeat.com - April 10 at 9:19 AM
Baillie Gifford & Co. Sells 1,974,073 Shares of NovoCure Limited (NASDAQ:NVCR)Baillie Gifford & Co. Sells 1,974,073 Shares of NovoCure Limited (NASDAQ:NVCR)
marketbeat.com - April 10 at 8:34 AM
NovoCure (NASDAQ:NVCR) Trading 4.9% Higher NovoCure (NASDAQ:NVCR) Trading 4.9% Higher
marketbeat.com - April 9 at 11:45 AM
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
businesswire.com - April 5 at 7:00 AM
NovoCure (NASDAQ:NVCR) Shares Gap Down  Following Analyst DowngradeNovoCure (NASDAQ:NVCR) Shares Gap Down Following Analyst Downgrade
marketbeat.com - April 3 at 1:36 PM
Wells Fargo & Company Lowers NovoCure (NASDAQ:NVCR) Price Target to $42.00Wells Fargo & Company Lowers NovoCure (NASDAQ:NVCR) Price Target to $42.00
marketbeat.com - April 3 at 1:35 PM
NovoCure (NVCR) Receives a Buy from Wells FargoNovoCure (NVCR) Receives a Buy from Wells Fargo
markets.businessinsider.com - April 3 at 1:35 AM
NovoCure (NASDAQ:NVCR)  Shares Down 6.6% NovoCure (NASDAQ:NVCR) Shares Down 6.6%
marketbeat.com - April 2 at 3:17 PM
NovoCure (NVCR) Moves to Buy: Rationale Behind the UpgradeNovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
zacks.com - April 1 at 1:00 PM
Novocure to Report First Quarter 2024 Financial ResultsNovocure to Report First Quarter 2024 Financial Results
finance.yahoo.com - April 1 at 10:35 AM
Why NovoCure Stock Soared 18.3% This WeekWhy NovoCure Stock Soared 18.3% This Week
fool.com - March 30 at 6:34 AM
NovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price TargetNovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price Target
markets.businessinsider.com - March 29 at 10:34 AM
Why Novocure Stock Is Jumping TodayWhy Novocure Stock Is Jumping Today
fool.com - March 28 at 11:50 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Agiliti logo

Agiliti

NYSE:AGTI
Agiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity. It also provides clinical engineering services comprising maintenance, repair, and remediation solutions for various types of medical equipment, including general biomedical equipment, diagnostic imaging equipment, and surgical equipment through supplemental and outsourced offerings. In addition, the company offers equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. It serves acute care hospitals, health systems and integrated delivery networks and alternate site providers. The company was founded in 1939 and is headquartered in Eden Prairie, Minnesota. Agiliti, Inc. operates as a subsidiary of THL Agiliti LLC.
Gyre Therapeutics logo

Gyre Therapeutics

NASDAQ:GYRE
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
National HealthCare logo

National HealthCare

NYSEAMERICAN:NHC
National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and sub-cute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company's homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, it offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.
NovoCure logo

NovoCure

NASDAQ:NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.